IE 11 is a very old Browser and it`s not supported on this site

Consolidated statement of cash flow

in CHF 1 000

 

Notes

 

01.01.–30.06.2023

 

01.01.–30.06.2022

Cash flows from operating activities

 

 

 

 

 

 

Proceeds from sales of securities

 

3

 

260 313

 

328 734

Purchase of securities

 

3

 

(28 135)

 

(46 042)

Interest receipts

 

 

 

17

 

Payments for services

 

 

 

(20 307)

 

(24 188)

Income taxes paid

 

 

 

(75)

 

(78)

Total cash flows from operating activities

 

 

 

211 813

 

258 426

 

 

 

 

 

 

 

Cash flows from financing activities

 

 

 

 

 

 

Dividend

 

 

 

(156 311)

 

(212 242)

Purchase of treasury shares

 

5

 

 

(18 484)

Repayment of borrowings

 

4

 

(54 500)

 

(29 000)

Interest payments

 

 

 

(2 550)

 

(591)

Total cash flows from financing activities

 

 

 

(213 361)

 

(260 317)

 

 

 

 

 

 

 

Foreign exchange difference

 

 

 

500

 

780

Change in cash and cash equivalents

 

 

 

(1 048)

 

(1 111)

 

 

 

 

 

 

 

Cash and cash equivalents at the beginning of the period

 

 

 

1 948

 

2 835

 

 

 

 

 

 

 

Cash and cash equivalents at the end of the period

 

 

 

900

 

1 724

The notes are an integral part of the condensed consolidated interim financial statements.

BB Biotech AG uses cookies to improve website usability and ensure the best possible user experience. Use of cookies & disclaimer